【 January 】

　Successfully obtained the import and distribution license for medical devices issued by the Government of the Republic of Indonesia

【 May 】

　The 2024 Edition of the 《CSCO Prostate Cancer Diagnosis and Treatment Guidelines》 has been updated and released, featuring Irreversible Electroporation (IRE) technology with prominent recommendations and interpretations

【 September 】

　The Composite Steep Pulse Therapeutic Device has earned the FDA Breakthrough Device Designation

【 September 】

　We are honored to receive the Second Prize in the Enterprise Category at the 2024 "Maker China" National Finals

【 September 】

　We are honored to receive the Second Prize of the 2024 Huaxia Medical Science and Technology Award

【 October 】

　Company Awarded Second Prize in 2024 Huaxia Medical Science and Technology Awards

【 October 】

　Company's Composite Steep Pulse Therapy Device Receives European Union (EU) CE Certification

【 October 】

　The NORTION Portable Composite Steep Pulse Therapeutic Device has been granted the Medical Device Registration Certificate for prostate cancer and hyperplasia indications

【 December 】

　The Composite Steep Pulse Therapeutic Device has been officially featured in the 《Shanghai Innovative and High-Quality Medical Products Catalog》

【 December 】

　Honored to receive the Second Prize of the Shanghai Outstanding Industry-University-Research Collaboration Projects

【 January 】

　The Nortion Medical high-frequency composite steep pulse treatment device was been successfully selected for "2022 Shanghai Innovative Product Recommendation Catalogue" in January

【 February 】

　Series A+ funding was completed in February

【 February 】

　The company was renamed as Shanghai Nortion Medical Technology Co., Ltd. in February

【 February 】

　The Medical Pulse Electric Field Ablation Equipment by Nortion was awarded as the 2023 "Science and Technology Innovation Action Plan" in February

【 March 】

　Nortion was awarded with the honorary title of "Shanghai Specialized, Refined, and New Small and Medium Enterprises" in March

【 May 】

　The company's Composite Steep Pulse Therapeutic Device has been selected for the "First Batch of Innovative Pharmaceuticals and Medical Devices Recommendation Catalog" of Pudong New Area

【 June 】

　Nortion was awarded with First Prize for Advance of Science and Technology, Outstanding Scientific Research Achievements (Science and Technology) in High Education Institutions by the Ministry of Education in June

【 July 】

　Nortion was awarded the title of "Little Giant" Enterprise at the national level for specialization, refinement, and innovation in July

【 September 】

　The company has been granted the world's first Class III medical device registration certificate for treating benign prostatic hyperplasia with irreversible electroporation technology.

【 September 】

　The company has successfully passed the acceptance review for its national key R&D program project and has been approved for the "Shanghai Enterprise Patent Work Pilot Project"

【 December 】

　The company has secured approval for two major Shanghai municipal initiatives:

　The 2023 Special Fund for Promoting High-Quality Industrial Development - Biomedicine Subprogram

　The 2023 Innovative Medical Device Application Demonstration Project

【 January 】

The company initiated a multicenter clinical trial for atrial fibrillation and completed the first pulse electric field ablation surgery for patients with atrial fibrillation in January

【 February 】

　Company Completes Enrollment of All 160 Subjects in Clinical Study on Composite Steep Pulse Therapy Device for Ablation Treatment of Benign Prostatic Hyperplasia (BPH)

【 July 】

　Nortion Pulse Field Ablation apparatus enters the Special Examination and Approval Procedure in July

【 November 】

　Nortion was successfully ranked as the "Top 50 Entrepreneurs with the Most Investment Potential in Shanghai in 2022" in November

【 November 】

　Nortion was been awarded as the "2022 Pudong New Area R&D Institution Recognition" and the "2022 Pudong New Area High Quality Development Project Approval" in November

【 December 】

　Nortion successfully won the "Excellent Award" in the 11th China Innovation and Entrepreneurship Competition in December

【 April 】

　Nortion compound steep pulse therapeutic apparatus was issued with Class IlI medical device registration Certificate and Production license in April

【 August 】

　Series A funding was completed in August

【 December 】

　Nortion was awarded as "Shanghai High Technology Expertise" in December

【 December 】

　The company initiated a multicenter clinical trial for liver cancer and completed the enrollment of the first liver cancer subject in December

【 April 】

　Project Undertaken by the Company Formally Approved for the 2019 National Key R&D Program "Research and Development of Digital Diagnosis and Treatment Equipment" Pilot Special Project under the Ministry of Science and Technology's *"National Science, Technology and Innovation Plan for the 13th Five-Year Plan"

【 July 】

　Company Initiates Clinical Study on Composite Steep Pulse Therapy Device for Ablation Treatment of Benign Prostatic Hyperplasia

【 September 】

　Nortion was officially obtained ISO13485 quality management system certification in September

【 November 】

　Nortion was approved with the project of the Pudong New Area Science and Technology Development (Biomedicine field) in November

【 May 】

　Company's Composite Steep Pulse Therapy Device Used in "Single-Arm Objective Performance Criteria Multi-Center Clinical Study for Prostate Cancer Tissue Ablation Treatment"

【 June 】

　Series Pre-A funding was completed in June

【 April 】

　Company's Composite Steep Pulse Therapy Device Used in "Single-Arm Objective Performance Criteria Multi-Center Clinical Study for Prostate Cancer Tissue Ablation Treatment"

【 April 】

　Nortion successfully obtained 2018 Shanghai “Science and Technology Innovation Action Plan” support project in April

【 July 】

　The company's Composite Steep Pulse therapeutic device has entered the special review procedure for innovative medical devices

【 March 】

　Nortion compound Steep pulse therapeutic apparatus was developed successfully in March

【 November 】

　Company's Composite Steep Pulse Therapy Device Completes Feasibility Study for Prostate Cancer Tissue Ablation Treatment

【 September 】

　Shanghai Nortion Medical Technology Co., Ltd. formally established in September

【 December 】

　The company has built its production and R&D base in the Shanghai Pudong International Medical Park